Riskpilot← Back to searchSign inGet full accessOctapharma AB
ABActiveOrg 5565504833Lars Forssells Gata 23Manufacture of pharmaceutical preparations · NACE 2120Est. 19971170 employees
Revenue 2025
SEK 2,7B
+5% vs 2024
EBITDA margin
4.7%
+6% vs 2024
Equity ratio
35.3%
Financial strength
Net profit 2025
SEK 59,9M
-40% vs 2024
| Revenue | SEK 2,7B | +5% |
| EBITDA | SEK 129,2M | +6% |
| Net profit | SEK 59,9M | -40% |
| Total assets | SEK 3,5B | +25% |
| Equity | SEK 1,2B | +5% |
| Employees | 1170 | — |
Legal name
Octapharma AB
Org number
5565504833
Legal form
Aktiebolag
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
15 december 1997
Share capital
SEK 25 000 000
Employees
1170 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av Clairotte, Olivier Claude Leo, Carola Christina Marguerre, Tobias Marguerre, Wolfgang Hubert Rosenqvist, Carl Pontus Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall tillverka, bedriva handel med och marknadsföra läkemedel samt därmed förenlig verksamhet.
Address
Lars Forssells Gata 23
Phone
+46856643000
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1 788 092 | 2 084 988 | 2 389 392 | 2 598 216 | 2 739 890 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 82 438 | 95 643 | 174 861 | 121 858 | 129 216 |
| Depreciation & amort. | — | — | — | — | — |
| EBIT | 82 438 | 95 643 | 174 861 | 121 858 | 129 216 |
| Net financials | −5 883 | −11 262 | 5 577 | −20 181 | −40 993 |
| Profit before tax | 102 186 | 236 445 | 249 537 | 127 139 | 79 223 |
| Tax | −21 036 | −50 250 | −53 455 | −27 891 | −19 290 |
| Net profit | 81 150 | 186 195 | 196 082 | 99 248 | 59 933 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 1 785 902 | 1 409 079 | 1 828 075 | 2 778 406 | 3 469 943 |
| Equity | 738 580 | 924 775 | 1 120 857 | 1 165 674 | 1 225 607 |
| Long-term debt | 500 000 | 0 | 271 778 | 1 130 471 | 1 636 106 |
| Short-term debt | 270 156 | 359 203 | 379 436 | 451 720 | 568 690 |
| Total debt | 770 156 | 359 203 | 651 214 | 1 582 191 | 2 204 796 |
EBITDA margin
4.7%
This company
15.8%
Market median
-70% vs market
20212025
Equity ratio
35.3%
This company
38.2%
Market median
+8% vs market
20212025
Return on equity
4.9%
This company
18.4%
Market median
-73% vs market
20212025
Net profit margin
2.2%
This company
8.1%
Market median
-73% vs market
20212025
Asset turnover
0.79×
This company
1.12×
Market median
-29% vs market
20212025
Debt / equity
1.83×
This company
0.62×
Market median
-195% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
CC Chief Executive Officer | Chief Executive Officer | 2024 |
CP Chief Executive Officer | Chief Executive Officer | 2025 |
ME Chief Auditor | Chief Auditor | 2019 |
| Former (2) | ||
KP Chief Auditor | Chief Auditor | 2019 – 2020 |
AA Chief Executive Officer | Chief Executive Officer | 2019 – 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (7) | ||
| Board of Directors | 2025 | |
| Board of Directors | 2019 | |
| Deputy Board Member | 2025 | |
| Deputy Board Member | 2025 | |
| Chairman | 2019 | |
| Board of Directors | 2025 | |
| Board of Directors | 2019 | |
| Former (5) | ||
| Chairman | 2019 – 2023 | |
| Board of Directors | 2019 – 2025 | |
| Board of Directors | 2019 – 2020 | |
| Deputy Board Member | 2019 – 2020 | |
| Board of Directors | 2019 – 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Octapharma Nordic AB
Octapharma AB Board members of Octapharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Klas Patrik Israelsson | Chief Auditor | 0 companies |
| Arthur Alexander Scheepers | Chief Executive Officer | 0 companies |
| Carola Christina Leo | Chief Executive Officer | 0 companies |
| Carl Pontus Rosenqvist | Chief Executive Officer | 0 companies |
| Maria Elias | Chief Auditor | 0 companies |
| Jan Olof Eriksson | Board of Directors | 0 companies |
| Eva Ann-Charlotte Hinz | Chairman | 0 companies |
| Jussi Petteri Raita | Board of Directors | 0 companies |
| Tobias Marguerre | Board of Directors | 0 companies |
| Karim Rasoli Koshsefat | Deputy Board Member | 0 companies |
| Monica Birgitta Tiemer | Deputy Board Member | 0 companies |
| Surasvadee Ning Vidlund | Board of Directors | 0 companies |
| Wolfgang Hubert Marguerre | Chairman | 0 companies |
| Cengiz Erdal | Board of Directors | 0 companies |
| Mats Eric Andersson | Deputy Board Member | 0 companies |
| Gerold Theo Rempeters | Board of Directors | 0 companies |
| Olivier Claude Clairotte | Board of Directors | 0 companies |